Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19 EUR | -0.03% | -7.27% | +13.88% |
Jun. 08 | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
Jun. 07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
- Stock Market
- Equities
- GSK Stock
- GS71 Stock
- News GSK plc
- Other languages